AbbVie (ABBV) News Today

Envestnet Portfolio Solutions Inc. raised its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 11.5% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 191,569 shares of the company's stock after acquiring an additional 19,828 shares during the perio

AbbVie (NYSE:ABBV) Stock Price Up 0.5% on Analyst Upgrade

Advisors Capital Management LLC increased its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 4.7% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 525,792 shares of the company's stock after purchasing an additional 23,518 shares du

AbbVie (NYSE:ABBV) Stock Price Up 0.5% on Analyst Upgrade

Morgan Stanley upped their price target on AbbVie from $191.00 to $196.00 and gave the company an "overweight" rating in a research report on Thursday.

Mediolanum International Funds Ltd purchased a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 256,922 shares of the company's stock, valued at approxima

AbbVie (NYSE:ABBV) Trading Down 0.1%

Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024

Central Pacific Bank Trust Division purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor purchased 14,403 shares of the company's stock, valued at approximately $2,603,000. Seve

AbbVie (NYSE:ABBV) Stock Price Up 0.8%

Cantor Fitzgerald reissued an "overweight" rating and issued a $200.00 target price on shares of AbbVie in a research note on Tuesday.

Daiwa Securities Group Inc. increased its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 14.4% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 192,589 shares of the company's stock after acquiring an add

AbbVie (NYSE:ABBV) Shares Up 0.1%

Palisade Asset Management LLC grew its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 65.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 97,341 shares of the company's stock after purchasing an additional 38,5

Mirae Asset Global Investments Co. Ltd. grew its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 20.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 722,755 shares of the company's stock after purc

The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season

Longbow Finance SA purchased a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 30,308 shares of the company's stock, valued at approximately $5,519,

AbbVie (NYSE:ABBV) Trading 0.6% Higher

AbbVie (NYSE:ABBV) updated its second quarter 2024 earnings guidance. The company provided EPS guidance of 2.530-2.570 for the period, compared to the consensus estimate of 3.050.

Svenska Handelsbanken AB publ purchased a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 182,749 shares of the company's stock, valued at approxima

In a holiday-shortened week, shares of AbbVie Inc. NYSE: ABBV are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson & Johnson NYSE: JNJ, which is down 0.68%, and Pfizer Inc. NYSE: PFE, which is down 1.38%.

ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors

In a holiday-shortened week, shares of AbbVie Inc. NYSE: ABBV are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson & Johnson NYSE: JNJ, which is down 0.68%, and Pfizer Inc. NYSE: PFE, which is down 1.38%.

AbbVie (NYSE:ABBV) Stock Price Down 0.2%

Raub Brock Capital Management LP trimmed its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 5.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 106,284 shares of the company's stock after

AbbVie Inc. (NYSE:ABBV - Get Free Report) was the target of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 15,250,000 shares, a drop of 7.5% from the May 31st total of 16,490,000 shares. Based on an average daily volume of 5,310,000 shares, the days-to-cover ratio is currently 2.9 days. Approximately 0.9% of the company's stock are short sold.

Piper Sandler reaffirmed an "overweight" rating and issued a $190.00 price objective on shares of AbbVie in a research note on Tuesday.

AbbVie (NYSE:ABBV) Shares Down 1.7%

Allspring Global Investments Holdings LLC grew its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 1.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 510,865 shares of the company's stock after purchasing an